Cargando…
Zero Echo Time (17)O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis
The cerebral metabolic rate of oxygen consumption (CMRO(2)) is a key metric to investigate the mechanisms involved in neurodegeneration in animal models and evaluate potential new therapies. CMRO(2) can be measured by direct (17)O magnetic resonance imaging ((17)O-MRI) of H(2)(17)O signal changes du...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145383/ https://www.ncbi.nlm.nih.gov/pubmed/33922384 http://dx.doi.org/10.3390/metabo11050263 |
_version_ | 1783697162090053632 |
---|---|
author | Baligand, Celine Barret, Olivier Tourais, Amélie Pérot, Jean-Baptiste Thenadey, Didier Petit, Fanny Liot, Géraldine Gaillard, Marie-Claude Flament, Julien Dhenain, Marc Valette, Julien |
author_facet | Baligand, Celine Barret, Olivier Tourais, Amélie Pérot, Jean-Baptiste Thenadey, Didier Petit, Fanny Liot, Géraldine Gaillard, Marie-Claude Flament, Julien Dhenain, Marc Valette, Julien |
author_sort | Baligand, Celine |
collection | PubMed |
description | The cerebral metabolic rate of oxygen consumption (CMRO(2)) is a key metric to investigate the mechanisms involved in neurodegeneration in animal models and evaluate potential new therapies. CMRO(2) can be measured by direct (17)O magnetic resonance imaging ((17)O-MRI) of H(2)(17)O signal changes during inhalation of (17)O-labeled oxygen gas. In this study, we built a simple gas distribution system and used 3D zero echo time (ZTE-)MRI at 11.7 T to measure CMRO(2) in the APP(swe)/PS1(dE9) mouse model of amyloidosis. We found that CMRO(2) was significantly lower in the APP(swe)/PS1(dE9) brain than in wild-type at 12–14 months. We also estimated cerebral blood flow (CBF) from the post-inhalation washout curve and found no difference between groups. These results suggest that the lower CMRO(2) observed in APP(swe)/PS1(dE9) is likely due to metabolism impairment rather than to reduced blood flow. Analysis of the (17)O-MRI data using different quantification models (linear and 3-phase model) showed that the choice of the model does not affect group comparison results. However, the simplified linear model significantly underestimated the absolute CMRO(2) values compared to a 3-phase model. This may become of importance when combining several metabolic fluxes measurements to study neuro-metabolic coupling. |
format | Online Article Text |
id | pubmed-8145383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81453832021-05-26 Zero Echo Time (17)O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis Baligand, Celine Barret, Olivier Tourais, Amélie Pérot, Jean-Baptiste Thenadey, Didier Petit, Fanny Liot, Géraldine Gaillard, Marie-Claude Flament, Julien Dhenain, Marc Valette, Julien Metabolites Article The cerebral metabolic rate of oxygen consumption (CMRO(2)) is a key metric to investigate the mechanisms involved in neurodegeneration in animal models and evaluate potential new therapies. CMRO(2) can be measured by direct (17)O magnetic resonance imaging ((17)O-MRI) of H(2)(17)O signal changes during inhalation of (17)O-labeled oxygen gas. In this study, we built a simple gas distribution system and used 3D zero echo time (ZTE-)MRI at 11.7 T to measure CMRO(2) in the APP(swe)/PS1(dE9) mouse model of amyloidosis. We found that CMRO(2) was significantly lower in the APP(swe)/PS1(dE9) brain than in wild-type at 12–14 months. We also estimated cerebral blood flow (CBF) from the post-inhalation washout curve and found no difference between groups. These results suggest that the lower CMRO(2) observed in APP(swe)/PS1(dE9) is likely due to metabolism impairment rather than to reduced blood flow. Analysis of the (17)O-MRI data using different quantification models (linear and 3-phase model) showed that the choice of the model does not affect group comparison results. However, the simplified linear model significantly underestimated the absolute CMRO(2) values compared to a 3-phase model. This may become of importance when combining several metabolic fluxes measurements to study neuro-metabolic coupling. MDPI 2021-04-22 /pmc/articles/PMC8145383/ /pubmed/33922384 http://dx.doi.org/10.3390/metabo11050263 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Baligand, Celine Barret, Olivier Tourais, Amélie Pérot, Jean-Baptiste Thenadey, Didier Petit, Fanny Liot, Géraldine Gaillard, Marie-Claude Flament, Julien Dhenain, Marc Valette, Julien Zero Echo Time (17)O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis |
title | Zero Echo Time (17)O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis |
title_full | Zero Echo Time (17)O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis |
title_fullStr | Zero Echo Time (17)O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis |
title_full_unstemmed | Zero Echo Time (17)O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis |
title_short | Zero Echo Time (17)O-MRI Reveals Decreased Cerebral Metabolic Rate of Oxygen Consumption in a Murine Model of Amyloidosis |
title_sort | zero echo time (17)o-mri reveals decreased cerebral metabolic rate of oxygen consumption in a murine model of amyloidosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145383/ https://www.ncbi.nlm.nih.gov/pubmed/33922384 http://dx.doi.org/10.3390/metabo11050263 |
work_keys_str_mv | AT baligandceline zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT barretolivier zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT touraisamelie zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT perotjeanbaptiste zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT thenadeydidier zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT petitfanny zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT liotgeraldine zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT gaillardmarieclaude zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT flamentjulien zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT dhenainmarc zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis AT valettejulien zeroechotime17omrirevealsdecreasedcerebralmetabolicrateofoxygenconsumptioninamurinemodelofamyloidosis |